Fifth Circuit: Louisiana Abortion Pill Mailing Block Scrutinized

• The Fifth Circuit Court of Appeals is reviewing Louisiana's request to block the FDA's 2023 decision that removed the in-person dispensing requirement for mifepristone.
• Louisiana argues it has legal standing due to Medicaid costs from telehealth abortion complications and the circumvention of state abortion bans by mailed pills.
• Judges questioned the panel's authority to issue such a block and the direct connection between the FDA's policy change and mifepristone being mailed into states where abortion is unlawful.
• The FDA permanently removed the in-person dispensing requirement for mifepristone in 2023, following a temporary suspension during the COVID-19 pandemic.
• A prior district court judge denied Louisiana's preliminary injunction request, noting that a nationwide ban on telehealth abortions would result if granted.

For legal professionals advising healthcare providers or pharmacies, the outcome of this Fifth Circuit decision is critical.

A panel of the U.S. Fifth Circuit Court of Appeals recently scrutinized Louisiana's renewed attempt to implement a Fifth Circuit Louisiana abortion pill mailing block. The state is not seeking to prohibit telehealth prescriptions for abortion medication outright. Instead, Louisiana has specifically requested that the court issue a stay on the U.S. Food and Drug Administration’s (FDA) 2023 decision, which removed the requirement for in-person dispensing of mifepristone, one of two drugs used in medication abortions. Furthermore, Louisiana is asking the judges to effectively "stay the stay" by suspending the panel's own decision while the U.S. Supreme Court reviews the underlying issue.

During the proceedings, U.S. Circuit Judge Stephen Higginson, an appointee of former President Barack Obama, raised questions regarding the panel's authority to block the FDA's action. This concern stems from a previous, unreasoned decision by the Supreme Court that had blocked an earlier panel's stay of the FDA's removal of the in-person dispensing requirement while the Fifth Circuit considered the case. Judge Higginson remarked that Louisiana's strategy of requesting a "stay the stay" appeared somewhat self-defeating, particularly given the state's argument that it faces irreparable harm necessitating the blocking of the FDA's decision. The three-judge panel also included U.S. Circuit Judge Priscilla Richman, a George W. Bush appointee, and U.S. Circuit Judge Dana Douglas, an appointee of President Joe Biden.

A central point of contention during the hearing was whether Louisiana possesses the necessary legal standing to challenge the FDA's decision. Louisiana asserts its standing on two primary grounds: first, the financial burden of Medicaid costs incurred from treating complications arising from telehealth abortions; and second, the claim that the mailing of abortion pills is being utilized to circumvent existing Louisiana laws that ban abortion. Louisiana Solicitor General Ben Aguiñaga stated that the state is experiencing approximately 1,000 abortions per month due to mifepristone mailed into the state.

However, Judge Richman expressed skepticism about the direct link between the FDA's removal of the mifepristone in-person dispensing requirement and the mailing of the drug into Louisiana. She noted difficulty in finding evidence within the record indicating that the FDA has approved the mailing of this medication into states where such actions are unlawful. This line of questioning highlights the complexities surrounding the FDA mifepristone dispensing requirement and the scope of federal versus state authority in regulating medication access.

The FDA's policy regarding mifepristone has undergone significant changes in recent years. In 2021, in response to the COVID-19 pandemic, the FDA temporarily suspended enforcement of a component of its Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, which had mandated in-person dispensing. This temporary measure allowed healthcare providers to prescribe the medication via telehealth and subsequently mail it to patients. Two years later, in 2023, the FDA made this change permanent, officially removing the in-person dispensing requirement for mifepristone.

Prior to the current Fifth Circuit proceedings, Louisiana had initiated a lawsuit to compel the FDA to reinstate the in-person dispensing requirement. The state argued that the FDA's determination regarding the safety of removing this requirement lacked sufficient supporting data. Last year, a review of the FDA's decision to allow abortions by mail was announced by Robert F. Kennedy Jr., identified in the source as President Donald Trump’s Health and Human Services Secretary. U.S. District Judge David Joseph, a Trump appointee for the Western District of Louisiana, ultimately denied the state's request for a preliminary injunction to reverse the removal of the in-person dispensing requirement. While Judge Joseph acknowledged that the FDA's decision was not adequately supported and that Louisiana was indeed experiencing irreparable harm through financial injury and the undermining of its abortion ban, he concluded that the balance of equities favored maintaining the removal of the in-person dispensing requirement while the FDA completed its review of the decision.

The ongoing legal battle, particularly the potential for a Fifth Circuit Louisiana abortion pill mailing block, carries substantial implications for abortion access across the United States. Judge Joseph, in his prior ruling, noted that issuing a preliminary injunction would result in a nationwide prohibition on telehealth abortions, affecting even states that do not oppose such practices. This underscores the broad reach of federal court decisions on matters of reproductive healthcare.

For legal professionals advising healthcare providers or pharmacies, the outcome of this Fifth Circuit decision is critical. It will directly determine the legality and compliance requirements for the remote dispensing of abortion medication, especially concerning interstate mailing. The court's eventual ruling on Louisiana's standing abortion pill challenge and the FDA's mifepristone in-person dispensing removal will shape the landscape for abortion pill telehealth mailing and could significantly alter how patients access these medications nationwide.

Lawyers advising healthcare providers or pharmacies must closely monitor the Fifth Circuit's decision on Louisiana's challenge to the FDA's mifepristone mailing policy, as it will determine the legality and compliance requirements for remote dispensing of abortion medication, particularly across state lines.

Source: Original reporting via Courthouse News Service